Schedule 13D ownership disclosure

OMEGA THERAPEUTICS INC

Common Stock, $0.001 par value per share · CUSIP: 68217N105

Event date: 2024-12-29

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Flagship V VentureLabs Rx Fund, L.P.Reported CIK 0001724939

    Shares: 1,088,470 · Class: 2%

  • Flagship Ventures Fund V, L.P.Reported CIK 0001627639

    Shares: 5,896,386 · Class: 10.6%

  • Flagship Ventures Fund V General Partner LLCReported CIK 0001724575

    Shares: 6,984,856 · Class: 12.6%

  • Flagship Pioneering Fund VI, L.P.Reported CIK 0001716926

    Shares: 8,617,413 · Class: 15.6%

  • Flagship Pioneering Fund VI General Partner LLCReported CIK 0001724957

    Shares: 8,617,413 · Class: 1.8%

  • Nutritional Health LTP Fund, L.P.Reported CIK 0001780956

    Shares: 970,588 · Class: 1.8%

  • Nutritional Health LTP Fund General Partner LLCReported CIK 0001780951

    Shares: 970,588 · Class: 1.8%

  • Flagship Pioneering Special Opportunities Fund II, L.P.Reported CIK 0001760283

    Shares: 7,508,693 · Class: 13.6%

  • Flagship Pioneering Special Opportunities Fund II General Partner LLCReported CIK 0001826217

    Shares: 7,508,693 · Class: 13.6%

  • FPN, L.P.Reported CIK 0001860062

    Shares: 1,617,646 · Class: 2.9%

  • FPN General Partner LLCReported CIK 0001860059

    Shares: 1,617,646 · Class: 2.9%

  • Flagship VentureLabs V, LLCReported CIK 0001724959

    Shares: 2,197,059 · Class: 4%

  • Flagship VentureLabs V Manager LLCReported CIK 0001768987

    Shares: 2,197,059 · Class: 4%

  • Flagship Pioneering Fund VII, L.P.Reported CIK 0001805916

    Shares: 1,329,324 · Class: 2.4%

  • Flagship Pioneering Fund VII General Partner LLCReported CIK 0001805917

    Shares: 1,329,324 · Class: 2.4%

  • Flagship Pioneering, Inc.Reported CIK 0001400240

    Shares: 22,240,723 · Class: 40.2%

  • Noubar AfeyanReported CIK 0001222012

    Shares: 29,225,579 · Class: 52.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-24-141669
Form type
SCHEDULE 13D/A
Filer
Flagship Ventures Fund V, L.P.
CIK
CIK 1627639
Filed
Dec 31, 2024
Reporting period
Dec 29, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub